June 19-23, 2023

For the first time, we will attend the Psychedelic Science conference, held this year in Denver, CO. Omar Hamid, PharmD, will represent O’Brien Pharmacy, with the goal of better understanding this therapy and its possible benefits for some of our patients.

The use of psychedelics for mental health disorders has been investigated for decades and peaked in the 60s during the counter culture movement. Ever since, their utility has been  minimal and the psychedelic landscape has been fraught with shifting political agendas and misinformation leading to significant underutilization of several very promising agents with very compelling evidence for a wide array of mental health disorders.

In recent years, the tide has shifted with a loosening of regulatory restrictions and a renewed focus on alternative treatments for mental health. Over the past decade, there have been a multitude of studies of psychedelics showing benefit for a wide array of mental health disorders, including depression, anxiety, PTSD, anorexia, addiction and several others.

Psychedelic Science ‘23 was a culmination of decades of research in psychedelic science and presented an opportunity for clinicians, old and new, to experience the rapidly developing field of psychedelic science. The next several years will likely see new drug approvals, including MDMA for PTSD, and the future is very bright for this emerging science.